drugset / Trial / NCT06920056

A Study of BGM0504 in Overweight or Obese Participants

NCT06920056

Phase 1 Completed 28 enrolled BrightGene Bio-Medical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the influence of BGM0504 injection on gastric emptying and Pharmacokinetics of metformin and warfarin in overweight or obese participants

Timeline

Start
2025-03-24
Primary completion
2025-07-25
Completion
2025-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule Oral
Subject BGM0504 Unknown 10 mg Subcutaneous
Subject Metformin Small molecule Oral
Subject Warfarin Small molecule Oral

Indications